http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Pulmonary Pneumatocele in a Pneumonia Patient
( Hyunbeom Kim ),( Sung Hyeok Ryou ),( Se Weon Kim ),( Goohyeon Hong ) 대한내과학회 2015 대한내과학회 추계학술대회 Vol.2015 No.1
Pulmonary pneumatoceles are air-filled thin-walled spaces within the lung, and are rare in adult cases of pneumonia. We report the case of a 74-year-old male who was admitted with a cough and sputum production. He had been treated with oral dexamethasone since a brain tumorectomy six months prior. Contrast-enhanced computed tomography (CT) of the chest revealed a large pneumatocele in the right middle lobe and peripheral pneumonic consolidation. Bronchoalveolar lavage (BAL) was performed; cultures identified extended-spectrum β-lactamase (ESBL) producing Proteus mirabilis. A four-week course of intravenous ertapenem was administered, and the pneumatocele with pneumonia resolved on follow-up chest CT. To the best of our knowledge, this is the first reported case of pulmonary pneumatocele caused by ESBL-producing P. mirabilis associated with pneumonia.
인휠 전기자동차의 구동 모터 전류센서 고장 허용 제어 연구
김현범(Hyunbeom Kim),전남주(Namju Jeon),이형철(Hyeongcheol Lee) 한국자동차공학회 2015 한국자동차공학회 학술대회 및 전시회 Vol.2015 No.11
This paper presents a fault-tolerant control algorithm for the in-wheel motor drive electric vehicle. The proposed fault-tolerant control algorithm is developed based on parity equation and current estimation method. The nonlinear permanent magnet synchronous motor (PMSM) model and a PMSM control algorithm are developed to simulate the fault-tolerant control algorithm. The simulation results the validity of the proposed fault tolerant control algorithm.
Lee, Hyunbeom,Choi, Jong Min,Cho, Joo-Youn,Kim, Tae-Eun,Lee, Hwa Jeong,Jung, Byung Hwa Elsevier 2018 Chemistry and physics of lipids Vol.214 No.-
<P><B>Abstract</B></P> <P>Rosuvastatin is a statin used to treat metabolic syndrome conditions, such as hyperlipidemia. It is relatively safe; however, fatal rhabdomyolysis or skeletal myopathy can sometimes occur. Therefore, to investigate the overall effects of rosuvastatin, including lipid lowering and adverse effects, metabolic profiling was performed using metabolomics and lipidomics after rosuvastatin administration. Specifically, the metabolic profiles between healthy subjects and patients with hyperlipidemia were compared and the metabolic changes related to the mechanism of the drug effect were proposed. Healthy volunteers (n = 32) and hyperlipidemic patients (n = 14) were orally administered rosuvastatin (20 mg) once a day for 3–8 weeks, and plasma and urine were collected. Metabolomics and lipidomics were performed using UHPLC-LTQ/Orbitrap/MS/MS for non-targeted analysis and UHPLC-TQ-MS/MS for targeted analysis. Using non-targeted analysis, we successfully profiled and identified 73 and 87 metabolites in healthy subjects and hyperlipidemia subjects, respectively. Through targeted analysis, we have also quantified 188 metabolites, including amino acids, biogenic amines, glycerophospholipids, and sphingolipids. The levels of L-carnitine, diacylglycerol, and acylcarnitines significantly decreased after rosuvastatin administration regardless of the group. The overall levels of fatty acids (FA) and lysophosphatidylcholines (LysoPC) increased, while phosphatidylcholines (PC) decreased only in the patient group. β-Oxidation decreased overall, while the production of polyunsaturated FA increased only in the hyperlipidemic patients. Using metabolic profiling, we have evaluated the alterations in the biochemical pathways, which may aid in a more detailed understanding of the effect of rosuvastatin. Patient-specific metabolomic and lipidomic profiles may serve as valuable markers for the understanding of the adverse effects associated with statin treatment.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Rosuvastatin decreases cholesterol, L-carnitine, acylcarnitine levels, and Lp-PLA<SUB>2</SUB> activity. </LI> <LI> PC levels decreased and FA and LysoPC levels increased significantly in the patient group with rosuvastatin. </LI> <LI> Polyunsaturated fatty acids such as arachidonic acid and linoleic acid in the patient group suggests impaired β-oxidation. </LI> <LI> Significantly increased glutamate may act as an alternative substrate to complement the energy impairment. </LI> <LI> Patient group specific upregulation of myristate and palmitate may lead to mitochondrial dysfunction. </LI> </UL> </P>
Development of GC-MS based cytochrome P450 assay for the investigation of multi-herb interaction
Oh, Hyun-A,Lee, Hyunbeom,Kim, Donghak,Jung, Byung Hwa Academic Press 2017 Analytical biochemistry Vol.519 No.-
<P><B>Abstract</B></P> <P>As drug interactions with cytochrome P450 enzymes become increasingly important in the field of drug discovery, a high-throughput screening method for analysing the effects of a drug is needed. We have developed a simple and rapid simultaneous analytical method using a cocktail approach for measuring the activities of seven cytochrome P450 enzymes (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4). Human liver microsomes were used as a source for the seven cytochrome P450 enzymes, and a gas chromatography-mass spectrometry (GC-MS) was used for analysing their activities. Kinetic studies and inhibition assays of CYP enzymes were performed using known substrates and inhibitors for validating and comparing the reaction rates and time-dependent activities between methods using each substrate versus a method using a cocktail solution. The optimized cocktail method was successfully applied to evaluate the effects of the decoction of Socheongryong-tang (SCRT) on cytochrome P450 enzymes. Our cocktail method provides a simultaneous high-throughput activity assay using GC-MS for the first time. This method is applicable for analysing the drug interactions of various plant-derived mixtures.</P>